Banner
  • Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Onyx Fails to Meet Study's Main Goal

Article

Despite failing to meet its primary endpoint of improving the overall survival rate of patients with non-small cell lung cancer, it wasn't all bad news for Onyx Pharmaceuticals.

Despite failing to meet its primary endpoint of improving the overall survival rate of patients with non-small cell lung cancer, it wasn’t all bad news for Onyx Pharmaceuticals.

On news of the late-stage cancer drug trial’s failure, shares of Onyx dropped as low as $42.75 by noon. But by the afternoon, the stock began to recover, hitting $43.27 and not too far off from the where it was ($43.56) at the opening bell on Wednesday.

Click to enlarge

Nexavar, co-developed by Onyx and Bayer HealthCare, is already approved in the U.S. and more than 100 other countries to treat patients with unresectable liver cancer and advanced kidney cancer. However, lung cancer is the most common form of cancer globally.

The study comparing Nexavar to a placebo was performed at more than 150 sites on 700 patients. Although the study didn’t improve the overall survival in patients with lung cancer — the main goal of the study — Onyx did report an improvement in the progression-free survival rate, which was the secondary goal.

Also, Bayer HealthCare submitted to the FDA a colorectal cancer drug developed with Onyx. Onyx will be paid royalties on sales if the drug is approved.

The information contained in this article should not be construed as investment advice or as a solicitation to buy or sell any stock.

Read more:

Eyes on Aveo’s Nexavar Competition

Dendreon Presents Provenge Data in African Americans

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice